Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gelsolin - BioAegis Therapeutics

Next Previous
X
Search
Drug Profile

Gelsolin - BioAegis Therapeutics

Alternative Names: Gelsolin recombinant; hu r-P gelsolin; pGSN; Recombinant human plasma gelsolin; rh gelsolin; rhu-pGSN; Solinex

Latest Information Update: 29 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brigham and Womens Hospital
  • Developer BioAegis Therapeutics; Critical Biologics Corporation
  • Class Anti-inflammatories; Antibacterials; Antifibrotics; Antineoplastics; Bronchodilators; Expectorants; Proteins
  • Mechanism of Action Interleukin 1 beta inhibitors; Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adult respiratory distress syndrome; COVID-19 pneumonia
  • Phase I/II Community-acquired pneumonia
  • Preclinical Inflammation
  • Discontinued Bronchitis; Cystic fibrosis; Systemic inflammatory response syndrome

Most Recent Events

  • 27 Feb 2024 Phase-II clinical trials in Adult respiratory distress syndrome in Spain, Netherlands, Italy, Belgium, Germany, Canada, United Kingdom, USA (IV)
  • 16 Oct 2023 BioAegis Therapeutics receives Biomedical Advance Research and Development Authority (BARDA) grant from US Department of Health and Human Services to advance gelsolin for the treatment of Acute respiratory distress syndrome
  • 24 May 2023 BioAegis Therapeutics completes a phase I trial (In volunteers) in USA (IV) (NCT05789745)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top